BioTissue
- Industry
- Healthcare Technology Systems
- Founded Year
- 1997
- Headquarters
- Miami, Florida, USA
- Employee Count
- 200
Key People
- Amy Tseng - President and CEO
- Chris McCarthy - Chief Financial Officer
- Dr. Scheffer C.G. Tseng - Chief Technology Officer
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with a strong background in medical technology and regenerative medicine.
Amy Tseng, as President and CEO, brings significant leadership experience in the MedTech industry. Dr. Scheffer C.G. Tseng, serving as Chief Technology Officer, provides deep expertise in regenerative medicine, enhancing the company's technical capabilities.
- Clinical Need
-
Aspect: Very Strong
Summary: BioTissue addresses critical unmet needs in regenerative medicine, particularly in ocular and surgical applications.
The increasing prevalence of chronic wounds and ocular disorders underscores the demand for effective regenerative treatments. BioTissue's products, derived from human birth tissue, offer innovative solutions in these areas.
- Competition
-
Aspect: Somewhat crowded
Summary: The regenerative medicine market is competitive, with several established players.
Competitors such as Organogenesis Inc., Integra LifeSciences Corporation, and MiMedx Group, Inc. are active in similar markets, offering alternative regenerative products.
- Technical Challenge
-
Aspect: Predictable
Summary: The technical challenges associated with BioTissue's products are manageable and well-understood.
BioTissue's CryoTek technology ensures the structural and functional preservation of amniotic membranes, facilitating consistent product quality and efficacy.
- Patent
-
Aspect: Strong
Summary: BioTissue holds strong patents protecting its proprietary technologies.
BioTissue's patents cover key aspects of its regenerative products and preservation technologies, safeguarding its innovations from competitors.
- Financing
-
Aspect: Medium
Summary: BioTissue has secured moderate funding to support its operations and growth.
The company's current financial resources support its existing product lines and R&D efforts, but further capital could enhance expansion initiatives.
- Regulatory
-
Aspect: 510k/PMA
Summary: BioTissue's products have received necessary regulatory approvals, facilitating market entry.
BioTissue has navigated the complex regulatory landscape to obtain approvals for its regenerative products, demonstrating commitment to quality and compliance.
Opportunity Rollup
- Odds of Success
- 3.65
- Peak Market Share
- 4.9
- Segment CAGR
- 25.1%
- Market Segment
- Regenerative Medicine
- Market Sub Segment
- Tissue Engineering
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.24 |
| 2 | 0.73 |
| 3 | 1.71 |
| 4 | 3.43 |
| 5 | 4.90 |
Key Takeaway
BioTissue is well-positioned in the rapidly growing regenerative medicine market, leveraging its experienced team and proprietary technologies to address significant clinical needs, despite facing competition and regulatory challenges.